Erica Stringer-Reasor
About
Erica Stringer-Reasor is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research.
According to data from OpenAlex, Erica Stringer-Reasor has authored 48 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Erica Stringer-Reasor's work include Cancer Treatment and Pharmacology (16 papers), HER2/EGFR in Cancer Research (16 papers) and Advanced Breast Cancer Therapies (15 papers). Erica Stringer-Reasor is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), HER2/EGFR in Cancer Research (16 papers) and Advanced Breast Cancer Therapies (15 papers). Erica Stringer-Reasor collaborates with scholars based in United States, Spain and United Kingdom. Erica Stringer-Reasor's co-authors include Suzanne D. Conzen, Gini F. Fleming, Katia Khoury, Maxwell N. Skor, Dongquan Chen, Masha Kocherginsky, Lizhong Wang, Lisa A. Newman, Andres Forero‐Torres and Melissa A. Simon and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.
In The Last Decade
Erica Stringer-Reasor
40 papers receiving 720 citations
Peers
Erica Stringer-Reasor
Neelima Vidula United States
CL Arteaga United States
Pietro De Placido Italy
Amelia Zelnak United States
Graham H.P. Richmond United Kingdom
Andrea Gombos Belgium
Daniele Andreis Italy
Santai Song China
Allen Saliganan United States
Alexandre Bodmer Switzerland
Citations per year, relative to Erica Stringer-Reasor Erica Stringer-Reasor (= 1×)
peers
Neelima Vidula
Countries citing papers authored by Erica Stringer-Reasor
Since
Specialization
Citations
This map shows the geographic impact of Erica Stringer-Reasor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erica Stringer-Reasor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erica Stringer-Reasor more than expected).
Fields of papers citing papers by Erica Stringer-Reasor
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Erica Stringer-Reasor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erica Stringer-Reasor. The network helps show where Erica Stringer-Reasor may publish in the future.
Co-authorship network of co-authors of Erica Stringer-Reasor
This figure shows the co-authorship network connecting the top 25 collaborators of Erica Stringer-Reasor. A scholar is included among the top collaborators of Erica Stringer-Reasor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erica Stringer-Reasor. Erica Stringer-Reasor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chen, Nan, Margarite D. Matossian, Murtuza Rampurwala, et al.. (2025). A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Research and Treatment. 211(1). 111–119.
2.
McConathy, Jonathan, Erica Stringer-Reasor, Gabrielle B. Rocque, et al.. (2025). Quantitative [89Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI. Journal of Nuclear Medicine. 66(7). jnumed.124.268931–jnumed.124.268931.
3.
González-Ericsson, Paula I., Nisha Unni, Komal Jhaveri, et al.. (2025). Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer. Clinical Cancer Research. 31(17). 3652–3661.
4.
Braunstein, Lior Z., Melissa P. Mitchell, Hanna Bandos, et al.. (2025). NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer. Future Oncology. 21(16). 2017–2025.
5.
Williams, Courtney, Ahmed Elkhanany, Katia Khoury, et al.. (2024). Therapeutic Clinical Trial Eligibility and Enrollment among Women with Breast Cancer: Implications for Understanding Trial Disparities. Annals of Surgical Oncology. 32(3). 2038–2044.
6.
Chen, Yan-Jun, Liton Francisco, Chen Dai, et al.. (2024). Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors. Journal of Clinical Oncology. 43(1). 32–45.
7.
O’Brien, Barbara, Rashmi K. Murthy, Donald A. Berry, et al.. (2024). Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.. Journal of Clinical Oncology. 42(16_suppl). 2018–2018.
8.
Gatsonis, Constantine, Heather A. Jacene, Roisín M. Connolly, et al.. (2024). Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial.. Journal of Clinical Oncology. 42(16_suppl). TPS614–TPS614.
9.
Meisel, Jane, Katia Khoury, A. Jo Chien, et al.. (2024). Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.. Journal of Clinical Oncology. 42(17_suppl). LBA509–LBA509.
10.
Ballinger, Tarah J., Fengmin Zhao, Joseph A. Sparano, et al.. (2024). ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.. Journal of Clinical Oncology. 42(17_suppl). LBA503–LBA503.
11.
Nanda, Rita, Ronald Cohen, Zoe Quandt, et al.. (2024). Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.. Journal of Clinical Oncology. 42(16_suppl). 584–584.
12.
Layman, Rachel M., Hyo S. Han, Hope S. Rugo, et al.. (2024). Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. The Lancet Oncology. 25(4). 474–487.
13.
Rugo, Hope S., Robert Wesolowski, Erica Stringer-Reasor, et al.. (2023). 204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients. ESMO Open. 8(1). 101393–101393.
14.
Vaklavas, Christos, Erica Stringer-Reasor, Ahmed Elkhanany, et al.. (2023). A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. Breast Cancer Research and Treatment. 198(2). 217–229.
15.
Chen, Nan, Murtuza Rampurwala, Sailaja Kamaraju, et al.. (2023). A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.. Journal of Clinical Oncology. 41(16_suppl). e13103–e13103.
16.
Dillon, Patrick M., Reva Basho, Hyo S. Han, et al.. (2023). Abstract OT1-03-06: Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress). Cancer Research. 83(5_Supplement). OT1–3.
17.
Curigliano, Giuseppe, Geoffrey I. Shapiro, Rebecca Kristeleit, et al.. (2022). A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. British Journal of Cancer. 128(1). 30–41.
18.
Maitland, Michael L., Jasgit C. Sachdev, Manish Sharma, et al.. (2021). First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. Clinical Cancer Research. 27(16). 4511–4520.
19.
Chien, A. Jo, Hatem Soliman, Judy C. Boughey, et al.. (2021). Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.. Journal of Clinical Oncology. 39(15_suppl). 508–508.
20.
Nanda, Rita, Erica Stringer-Reasor, Masha Kocherginsky, et al.. (2016). A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. SpringerPlus. 5(1). 947–947.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Neelima Vidula Breakdown of academic impact, for papers by CL Arteaga Breakdown of academic impact, for papers by Pietro De Placido Breakdown of academic impact, for papers by Amelia Zelnak Breakdown of academic impact, for papers by Graham H.P. Richmond Breakdown of academic impact, for papers by Andrea Gombos Breakdown of academic impact, for papers by Daniele Andreis Breakdown of academic impact, for papers by Santai Song Breakdown of academic impact, for papers by Allen Saliganan Breakdown of academic impact, for papers by Alexandre Bodmer